SGLT2抑制剂与外科主动脉瓣置换术后结局
本研究回顾2014至2025年接受外科主动脉瓣置换术(伴或不伴冠状动脉旁路移植术)的患者,倾向性评分匹配后比较使用与未使用SGLT2抑制剂的临床结局。共纳入2930例患者,其中85例(2.9%)使用SGLT2抑制剂。使用SGLT2抑制剂与5年全因死亡率显著降低相关,匹配后死亡率仍较低,且卒中发生率降低,心房颤动或再住院无显著差异。
要点
- 心房颤动入院或再住院无显著差异;观察性发现需前瞻性随机研究验证。
核心结论
- 在外科主动脉瓣置换术患者中,围术期使用SGLT2抑制剂与5年生存改善和卒中风险降低相关。
- 这些观察性发现具有假设生成性,支持在外科瓣膜人群中进行前瞻性随机研究。
研究设计与样本
- 回顾性队列研究,纳入2014至2025年接受外科主动脉瓣置换术或联合冠状动脉旁路移植术的患者。
- 共2930例患者,年龄76(69-83)岁,女性占40.3%,其中85例(2.9%)接受SGLT2抑制剂治疗。
- 使用倾向性评分匹配调整基线差异。
主要发现
- 心房颤动入院或再住院无显著差异。
临床怎么用
- 对于符合纳入标准(左心室射血分数≤40%、估算肾小球滤过率25-75 mL/min/1.73 m²或2型糖尿病)的外科主动脉瓣置换术患者,围术期使用SGLT2抑制剂可能与改善5年生存和降低卒中风险相关。
- 需注意证据为观察性,应个体化评估并等待随机试验证实。
局限性
- 观察性研究设计,存在残余混杂可能。
- SGLT2抑制剂使用比例低(2.9%),样本量有限。
- 作者指出发现为假设生成性,需前瞻性随机研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors have demonstrated mortality and heart failure hospitalization benefits across cardiovascular populations. However, their impact on patients with severe aortic stenosis undergoing surgical aortic valve replacement, with or without concomitant coronary artery bypass grafting, remains unclear. This study evaluated clinical outcomes associated with sodium-glucose cotransporter 2 inhibitor use in a real-world surgical aortic valve replacement population. METHODS: Patients who underwent surgical aortic valve replacement or combined surgical aortic valve replacement and coronary artery bypass grafting between 2014 and 2025 were reviewed. The inclusion criteria were consistent with contemporary trials including severe aortic valve replacement with left ventricular ejection fraction 40% or less, estimated glomerular filtration rate 25 to 75 mL/min/1.73 m2, or type 2 diabetes mellitus. Propensity score matching was used to adjust for baseline differences. The primary outcome was all-cause mortality. Secondary outcomes included stroke, heart failure hospitalization, atrial fibrillation admission, and all-cause rehospitalization. RESULTS: A total of 2930 patients (age 76 [69-83] years, 40.3% female) were included, of whom 85 (2.9%) received sodium-glucose cotransporter 2 inhibitor therapy. In the overall cohort, sodium-glucose cotransporter 2 inhibitor use was associated with significantly lower 5-year all-cause mortality compared with nonuse (13.6% vs 33.5%, log-rank P = .022). After matching, mortality remained lower among sodium-glucose cotransporter 2 inhibitor users (13.8% vs 25.8%, P = .012), with reduced stroke incidence (2.0% vs 19.3%; P = .046) and no significant differences in atrial fibrillation or rehospitalization. CONCLUSIONS: In patients undergoing surgical aortic valve replacement, perioperative sodium-glucose cotransporter 2 inhibitor therapy was associated with improved 5-year survival and reduced stroke risk. These observational findings are hypothesis generating and support further investigation of sodium-glucose cotransporter 2 inhibitors in prospective, randomized studies in the surgical valve population.
引用
- Jacquemyn X, Hasan I, Ogami T, et al. Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2026. PMID: 41831709. doi:10.1016/j.jtcvs.2026.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。